Piotr Wysocki: SABCS2023 – Adjuvant chemoimmunotherapy does not benefit TNBC patients

Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn:

“SABCS2023 – Adjuvant chemoimmunotherapy does not benefit TNBC patients

A large phase 3 ALEXANDRA/IMpassion030 study evaluated the addition of atezolizumab to standard adjuvant chemotherapy 12xPaclitaxel –> 4x ddAC/EC in a population of stage II-III TNBC patients (N=2300). After a median follow-up of approx. 25 months the study failed to demonstrate the benefit of adding atezolizumab to chemotherapy with HR for iDFS (primary endpoint) – 1.12 (95% CI 0.87–1.45) p=0.37.

This study clearly supports the current standard of using chemoimmunotherapy in neoadjuvant settings in TNBC patients. However, the question if adjuvant immunotherapy is needed in patients treated with neoadjuvant chemoimmunotherapy still remains unanswered.”

Source: Piotr Wysocki/LinkedIn